These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17307094)

  • 1. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 2. Rimonabant in obese patients with type 2 diabetes.
    Shapiro H; Singer P
    Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
    [No Abstract]   [Full Text] [Related]  

  • 3. Rimonabant in obese patients with type 2 diabetes.
    Roberfroid D
    Lancet; 2007 Feb; 369(9561):553; author reply 554-5. PubMed ID: 17307092
    [No Abstract]   [Full Text] [Related]  

  • 4. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
    Gadde KM
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
    J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of rimonabant on weight reduction and cardiovascular risk.
    Esposito K; Giugliano D
    Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacotherapy for obesity--promise and uncertainty.
    Yanovski SZ
    N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rimonabant on weight reduction and cardiovascular risk.
    Astrup A
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
    [No Abstract]   [Full Text] [Related]  

  • 13. Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
    McCall AL
    Curr Diab Rep; 2007 Oct; 7(5):329-32. PubMed ID: 18173964
    [No Abstract]   [Full Text] [Related]  

  • 14. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
    Green JB; Feinglos MN
    Curr Diab Rep; 2007 Oct; 7(5):369-75. PubMed ID: 18173970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 18. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
    Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.
    Cervino C; Pasquali R; Pagotto U
    Mini Rev Med Chem; 2007 Jan; 7(1):21-30. PubMed ID: 17266634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.